search
Back to results

Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Robotic-assisted Coronary Surgical Revascularization
PCI- Drug Eluting Stents
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary Artery Disease, PCI, Drug eluting stents, Coronary Hybrid Revascularization, Robotic CABG

Eligibility Criteria

30 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with class A or B1 low risk coronary artery lesion as defined by TIMI Exclusion Criteria: Contraindications to PCI which include: Occluded coronary vessels, PVD, Unable to achieve access, Fresh thrombus, Vessels <1.5mm Contraindications to Robotic Surgery which include: Buried LAD, Unable to tolerate single lung ventilation, Inability to undergo beating heart surgery, Previous surgery of the left chest cavity, Lack of intrathoracic work space, Patients requiring emergency surgery, The following patients are also excluded: Patients with coagulation disorders; inability to tolerate GIIb/III inhibitors, Patients with ventricular arrhythmias, Patients with severe non-cardiac conditions with poor prognosis, Patients with a BMI >40, Patients with an ejection fraction of <30%, Patients with chronic renal insufficiency and creatinine >200umol/L, Patients who are >85 years of age, Patients participating in any other investigational device or study drug, Patients who have had previous thoracic surgery, Patients who have a pre-op intra-aortic balloon pump, Patients who are not able to follow the protocol requirements, Patients undergoing concomitant surgery; CABG + Valve surgery

Sites / Locations

  • The London Health Sciences Centre, University Hospital

Outcomes

Primary Outcome Measures

Safety & efficacy of integrated myocardial revascularization performed in a single stage

Secondary Outcome Measures

One-year postoperative stenosis rate (Stenosis may be evaluated by the angiographic documentation of blood flow).
Success rate is defined as a reduction in stenosis to < 50%.
Myocardial infarction,
Death,
Repeat revascularization at any time after the robotic hybrid revascularization (Repeat revascularization are those involving a previously treated lesionfollowing the initial hybrid procedure)
In-hospital complications during or after surgery,
Inability to revascularize with the use of both stenting and LIMA to LAD bypass,
Inability to revascularize with the use of the da Vinci Surgical System

Full Information

First Posted
August 16, 2006
Last Updated
August 25, 2017
Sponsor
Lawson Health Research Institute
Collaborators
Canada Foundation for Innovation, Ontario Innovative Trust, Ontario Research and Development Challenge Fund
search

1. Study Identification

Unique Protocol Identification Number
NCT00366015
Brief Title
Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room
Official Title
Same Procedure Cardiac Hybrid Surgery in a Specialty Built OR-- A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
July 29, 2003 (Actual)
Primary Completion Date
December 31, 2010 (Actual)
Study Completion Date
December 31, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute
Collaborators
Canada Foundation for Innovation, Ontario Innovative Trust, Ontario Research and Development Challenge Fund

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will combine coronary stenting with minimally invasive robotic coronary bypass surgery, accomplished with the use of the da Vinci robot, to restore blood flow to occluded coronary arteries. Two previously approved and commonly performed procedures used to treat coronary artery disease(coronary stenting and robotic bypass surgery) are being combined into a hybrid surgery in a specialty built operating room. Patients with low risk coronary lesions will undergo cardiac hybrid revascularization using stenting and LIMA to LAD robotic bypass concomitantly. Patients' postoperative bleeding rates, angiographs and complication free rates will be recorded.
Detailed Description
Coronary artery disease (CAD) is the leading cause of death in the United States and becomes more common as the population ages (American Heart Association, 2003). The symptoms of CAD may not become perceptible until the condition has advanced to a severe and serious stage, which might explain the large mortality and morbidity rates associated with heart disease. At this point there are many procedures available to treat CAD all of which aim to improve myocardial blood flow, stop angina, increase exercise ability and ultimately free patients from medications and improve their quality of life. Medications are used to reduce blood pressure and relieve strain on the heart. Cardiologists use angioplasty, which compresses plaque deposits, and stenting, in which a small wire mesh tube is inserted into the diseased artery to revascularize the heart muscle. On-pump coronary artery bypass grafting (CABG) redirects blood flow around clogged vessels of the heart and is commonly used by cardiac surgeons to treat CAD because it has been proven to yield the lowest restenosis rate of all revascularization techniques (Cisowski, 2002). CABG is an effective yet painful and traumatic intervention. The desire to discover a less distressing approach to coronary artery revascularization has led to a fairly new cardiac hybrid procedure that involves stenting followed by a minimally invasive left internal mammary artery (LIMA) to left anterior descending artery (LAD) bypass graft (Amodeo, 2002). The hybrid procedure for revascularization carries a lower morbidity than does on-pump CABG and is also quickly gaining acceptance in the surgical community (de Canniere et al, 2001). The two procedures of hybrid revascularization are currently performed within 24 to 48 hours of each other with little collaboration between cardiac surgeons and cardiologist. This study will asses the efficacy and safety of cardiac hybrid surgery that combines stenting and robotic LIMA to LAD grafting in the same procedure in a specialty built operating room. Long term use of the antiplatelet inhibitor, clopidogrel, to be taken by patients in this study, was proven to significantly reduce the risk of adverse ischemic events after percutaneous coronary interventions (Steinhubl, 2002). In addition, the application of Bivalirudin (Direct Thrombin Inhibitor) will be assessed in this integrated myocardial revascularization scenario. The many attractive aspects of robotic hybrid bypass include the avoidance of the procedural phases (arrested heart, blood transfusion, median sternotomy and cardiopulmonary bypass) of on-pump CABG. Robotic LIMA to LAD bypass and stenting in the same procedure will allow cardiac surgeons and cardiologists to work together to help patients obtain safe and effective coronary artery revascularization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Coronary Artery Disease, PCI, Drug eluting stents, Coronary Hybrid Revascularization, Robotic CABG

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Robotic-assisted Coronary Surgical Revascularization
Intervention Description
Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
Intervention Type
Procedure
Intervention Name(s)
PCI- Drug Eluting Stents
Intervention Description
Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
Primary Outcome Measure Information:
Title
Safety & efficacy of integrated myocardial revascularization performed in a single stage
Time Frame
5 years post end of study
Secondary Outcome Measure Information:
Title
One-year postoperative stenosis rate (Stenosis may be evaluated by the angiographic documentation of blood flow).
Time Frame
One year
Title
Success rate is defined as a reduction in stenosis to < 50%.
Time Frame
One year
Title
Myocardial infarction,
Time Frame
within 30 days of surgery
Title
Death,
Time Frame
within 30 days of surgery and/or within primary hospitalization
Title
Repeat revascularization at any time after the robotic hybrid revascularization (Repeat revascularization are those involving a previously treated lesionfollowing the initial hybrid procedure)
Time Frame
One year
Title
In-hospital complications during or after surgery,
Time Frame
within initial hospitalization or within 30 days of discharge
Title
Inability to revascularize with the use of both stenting and LIMA to LAD bypass,
Time Frame
within initial hospitalization
Title
Inability to revascularize with the use of the da Vinci Surgical System
Time Frame
within initial hospitalization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with class A or B1 low risk coronary artery lesion as defined by TIMI Exclusion Criteria: Contraindications to PCI which include: Occluded coronary vessels, PVD, Unable to achieve access, Fresh thrombus, Vessels <1.5mm Contraindications to Robotic Surgery which include: Buried LAD, Unable to tolerate single lung ventilation, Inability to undergo beating heart surgery, Previous surgery of the left chest cavity, Lack of intrathoracic work space, Patients requiring emergency surgery, The following patients are also excluded: Patients with coagulation disorders; inability to tolerate GIIb/III inhibitors, Patients with ventricular arrhythmias, Patients with severe non-cardiac conditions with poor prognosis, Patients with a BMI >40, Patients with an ejection fraction of <30%, Patients with chronic renal insufficiency and creatinine >200umol/L, Patients who are >85 years of age, Patients participating in any other investigational device or study drug, Patients who have had previous thoracic surgery, Patients who have a pre-op intra-aortic balloon pump, Patients who are not able to follow the protocol requirements, Patients undergoing concomitant surgery; CABG + Valve surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bob Kiaii, MD, FRCSC
Organizational Affiliation
Department of Cardiac Surgery, University of Western Ontario and the London Health Sciences Centre, University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The London Health Sciences Centre, University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
14992900
Citation
Merry AF, Raudkivi PJ, Middleton NG, McDougall JM, Nand P, Mills BP, Webber BJ, Frampton CM, White HD. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004 Mar;77(3):925-31; discussion 931. doi: 10.1016/j.athoracsur.2003.09.061.
Results Reference
background
PubMed Identifier
14759391
Citation
Koster A, Spiess B, Chew DP, Krabatsch T, Tambeur L, DeAnda A, Hetzer R, Kuppe H, Smedira NG, Lincoff AM. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2004 Feb 1;93(3):356-9. doi: 10.1016/j.amjcard.2003.10.021.
Results Reference
background
PubMed Identifier
16678575
Citation
Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, Cates CU. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. J Thorac Cardiovasc Surg. 2006 May;131(5):956-62. doi: 10.1016/j.jtcvs.2005.10.058. Epub 2006 Apr 27.
Results Reference
background
PubMed Identifier
16820621
Citation
Katz MR, Van Praet F, de Canniere D, Murphy D, Siwek L, Seshadri-Kreaden U, Friedrich G, Bonatti J. Integrated coronary revascularization: percutaneous coronary intervention plus robotic totally endoscopic coronary artery bypass. Circulation. 2006 Jul 4;114(1 Suppl):I473-6. doi: 10.1161/CIRCULATIONAHA.105.001537.
Results Reference
background
PubMed Identifier
12142196
Citation
Cisowski M, Morawski W, Drzewiecki J, Kruczak W, Toczek K, Bis J, Bochenek A. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization. Eur J Cardiothorac Surg. 2002 Aug;22(2):261-5. doi: 10.1016/s1010-7940(02)00262-2.
Results Reference
background
PubMed Identifier
10047645
Citation
Zenati M, Cohen HA, Griffith BP. Alternative approach to multivessel coronary disease with integrated coronary revascularization. J Thorac Cardiovasc Surg. 1999 Mar;117(3):439-44; discussion 444-6. doi: 10.1016/s0022-5223(99)70322-3.
Results Reference
background
PubMed Identifier
8602013
Citation
Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation. Lancet. 1996 Mar 16;347(9003):757-8. doi: 10.1016/s0140-6736(96)90107-5. No abstract available.
Results Reference
background
PubMed Identifier
15919329
Citation
Bonatti J, Schachner T, Bonaros N, Laufer G, Kolbitsch C, Margreiter J, Jonetzko P, Pachinger O, Friedrich G. Robotic totally endoscopic coronary artery bypass and catheter based coronary intervention in one operative session. Ann Thorac Surg. 2005 Jun;79(6):2138-41. doi: 10.1016/j.athoracsur.2003.12.074.
Results Reference
background
PubMed Identifier
16112943
Citation
Bonatti J, Schachner T, Bonaros N, Jonetzko P, Ohlinger A, Lockinger A, Stalzer B, Eschertzhuber S, Friedrich G. Treatment of double vessel coronary artery disease by totally endoscopic bypass surgery and drug-eluting stent placement in one simultaneous hybrid session. Heart Surg Forum. 2005;8(4):E284-6. doi: 10.1532/HSF98.20051136.
Results Reference
background
PubMed Identifier
12063459
Citation
Dogan S, Aybek T, Andressen E, Byhahn C, Mierdl S, Westphal K, Matheis G, Moritz A, Wimmer-Greinecker G. Totally endoscopic coronary artery bypass grafting on cardiopulmonary bypass with robotically enhanced telemanipulation: report of forty-five cases. J Thorac Cardiovasc Surg. 2002 Jun;123(6):1125-31. doi: 10.1067/mtc.2002.121305.
Results Reference
background

Learn more about this trial

Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room

We'll reach out to this number within 24 hrs